argenx N.V.'s position as one of the crown jewels of the European biotech sector, and a rumored takeover target for big pharma, has been enhanced by positive late-stage data on its pipeline-in-a-product Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP).
The Belgian-Dutch group has unveiled topline results from the Phase III ADHERE study evaluating the subcutaneous version of the drug,...